Combined Pulmonary Fibrosis and Emphysema Syndrome Complicated by Lung Cancer

Nesrin Kıral Gürbüz, Saadet Akkuş, Banu Salepçi, Sevda Şener Cömert, Elif Torun Parmaksız, Coşkun Doğan

INTRODUCTION

Combined pulmonary fibrosis and emphysema syndrome (CPFE) is a rare disease characterized by emphysema in the upper lobes of the lung and fibrosis in the lower lobes. Characteristic features of these cases are a reduction in preserved lung volume and a decrease in diffusion capacity for carbon monoxide (DLCO) in smokers, advanced age, and male gender.[1–3] Since these patients have a different clinical course and mortality rate from patients with only emphysema or fibrosis, establishment of the diagnosis is important. This syndrome is often complicated by pulmonary hypertension, acute lung injury, and lung cancer (LC).[2]

Since most patients with CPFE are smokers, CPFE is an important risk factor for LC.[4] Although CPFE may increase the risk of LC, the prevalence of CPFE in patients with LC and the incidence of LC in patients with CPFE are unknown.[5] This case is presented to draw attention to a potential association between CPFE and LC.

CASE REPORT

A 61-year-old male patient with a history of a 65 pack-years of cigarette smoking applied to policlinic with lower respiratory tract symptoms and received treatment for a lung abscess. He was then referred to our hospital since there is no radiological regression (Fig. 1).

The computed tomography (CT) of thorax revealed a 60×51 mm mass lesion demonstrating cavitation, para-aortic and paratracheal lymphadenopathies and bullous changes in the upper lobes, emphysema, fibrosis in the lower lobes, and a honeycomb appearance in the left lower lobe of the lung (Figs. 2, 3). Pulmonary parenchymal findings on a thorax CT were evaluated as consistent with CPFE.

ABSTRACT

Combined pulmonary fibrosis and emphysema syndrome (CPFE) is a rare disease characterized by emphysema in the upper lobes of the lung and fibrosis in the lower lobes. CPFE is an important risk factor for lung cancer (LC). Although CPFE might increase the risk of LC, the prevalence of CPFE in patients with LC and the incidence of LC in patients with CPFE are unknown.[5] This case is presented to draw attention to the possibility that it may be accompanied by LC.
The mass in the left lower lobe of the lung was also thought to be consistent with malignancy. The patient underwent pulmonary function tests (PFT) and the following values were obtained: forced vital capacity (FVC): 3.39 (79%), forced expiratory volume in one second (FEV): 2.58 (77%), FEV/FVC: 76, DLCO: 46%, DLCO/alveolar volume (VA): 60%. A transthoracic fine needle aspiration biopsy was performed on the mass lesion in the left lower lobe of the lung after consulting with an interventional radiologist.

The pathology report indicated squamous cell carcinoma. A positron emission tomography CT revealed a hypermetabolic mass on the left lower lobe of the left lung, hypermetabolic mass formation consistent with primary lung malignancy, hypermetabolic lymph nodes consistent with metastasis in multiple mediastinal and abdominal lymphatics, hypermetabolic lesions consistent with metastasis in the liver, both kidneys, and the L3 vertebra. The disease was evaluated as stage 4 lung cancer and the patient was directed to the medical oncology department for treatment. It was learned that the patient died 2 months later.

**DISCUSSION**

Idiopathic pulmonary fibrosis (IPF) and emphysema are distinct diseases with different radiological, pathological, functional, and prognostic features. However, a new entity was first described by Cottin in 2005 as coexisting with emphysema and pulmonary fibrosis with characteristic features and defined as CPFE. Recently, cases of CPFE have been published in the literature.[6,7]

CPFE is a newly identified syndrome characterized by specific clinical findings and radiological identification with upper lobe emphysema and lower lobe fibrosis. Since the disease is not well known, diagnosis remains inadequate. Although there is not yet a consensus definition, the characteristic clinical features are used as a guide in diagnosis of this disease: male gender, heavy smoking, partial preservation observed in a PFT, marked reduction in DLCO, presence of severe symptoms, pulmonary hypertension, and a high incidence of LC.[8]

Smoking is considered to be the most important risk factor in the etiology of CPFE.[1,2,9] A history of smoking was found in 98% of 607 patients in a meta-analysis.[2] In the same study, it was observed that 90% of the patients were male. Emphysema has been reported to be more common in male smokers than in female smokers.[2] Presently described is the case of a 61-year-old male patient with a 65 pack-year smoking history.

It is thought that 35% of all idiopathic pulmonary fibrosis (IPF) patients are actually cases of CPFE, and in current studies, high rates of emphysema (8–50%) have been reported in patients whose high-resolution computer tomography (HRCT) revealed the presence of pulmonary fibrosis[2,14,11] It is important to be able to define this disease, as the clinical course of CPFE differs from that of IPF.[7]

CPFE syndrome is radiologically characterized by emphysema in the upper lobes and interstitial fibrosis in the lower lobe.
lower lobes. In the upper lobes, paraseptal emphysema is more frequent, but centrilobular emphysema and bullous changes may be also seen. In the lower lobes, honeycomb cysts, an increase in reticular densities, and areas with a ground glass appearance may be encountered. The radiological findings in this case were also characterized by bullous changes, emphysema in the upper lobes specific to CPFE, interstitial fibrosis, honeycomb cysts, and increased reticular density in the lower lobes.

PFT results for lung volume and air flow are usually normal or slightly decreased. This is due to the adverse effects of fibrosis and emphysema on respiratory functions. It is characterized by severe reduction in DLCO. The reduction in DLCO is a common finding of emphysema, fibrosis, and pulmonary vascular injury. In our patient, the FEV1 was partially preserved (77%) while the DLCO was determined to be extremely low at 46%.

CPFE is often complicated by pulmonary hypertension, LC, or acute lung injury. Patients with CPFE are at increased risk for developing pulmonary hypertension, which is associated with a poor prognosis. Pulmonary hypertension is more common and more severe in patients with CPFE than in cases of chronic obstructive pulmonary disease (COPD) and IPF. Mortality is a particular concern in the presence of pulmonary hypertension.

CPFE is an important risk factor for LC because most CPFE patients are smokers. Although CPFE may increase the risk of LC, the prevalence of LC in patients with LC and the incidence of LC in patients with CPFE are unknown. The prevalence of LC in CPFE patients has been reported to be higher (35.8–46.8%). Kitaguchi et al. reported that the prevalence of LC in CPFE patients was significantly higher than that of patients with COPD (46.8% versus 7.3%). In a study of the HRCTs of 1143 patients with LC, CPFE was found in 101 patients (8.9%), emphysema in 404 (35.3%), and fibrosis in 15 (1.3%). In their large cohort study, Usui et al. found that the prevalence of LC in CPFE patients was significantly higher than that of patients with COPD (46.8% versus 7.3%). In a study of the HRCTs of 1143 patients with LC, CPFE was found in 101 patients (8.9%), emphysema in 404 (35.3%), and fibrosis in 15 (1.3%). In their large cohort study, Usui et al. found that the prevalence of LC in CPFE patients was significantly higher than that of patients with COPD (46.8% versus 7.3%). In a study of the HRCTs of 1143 patients with LC, CPFE was found in 101 patients (8.9%), emphysema in 404 (35.3%), and fibrosis in 15 (1.3%). In their large cohort study, Usui et al. found that the prevalence of LC in CPFE patients was significantly higher than that of patients with COPD (46.8% versus 7.3%).

The histological features of LC remain unclear in patients with both LC and CPFE. In a retrospective study of the data of 985 patients who underwent resection for primary LC, when compared with cases without CPFE, 72 CPFE cases with LC were found to be significantly associated with squamous cell carcinoma histology (n=46, p<0.001) and a higher tumor grade (n=44, p=0.001).

In the same study, it was stated that in most patients with LC and CPFE, the lesion was adjacent to the fibrotic zones (n=59, 81.9%) in the tumor periphery and that this relationship was independent of the tumor location. This study demonstrated that LC with CPFE has a different histological phenotype. It may originate from dysplastic epithelium in the fibrotic area surrounding the tumor, which is also associated with poor survival outcomes.

Maeda et al. investigated the clinicopathological features of 218 patients operated on due to a diagnosis of stage 1 non-small cell lung cancer. The 5-year recurrence-free survival rate of CPFE patients was 36%, which was significantly lower than those without CPFE (82%; p<0.001). In multivariate analysis, the presence of CPFE was found to be one of the statistically significant independent predictors of tumor recurrence (p=0.005).

CPFE syndrome generally has a poor prognosis, and a 5-year survival rate of 35% to 80% has been reported. The average survival of patients with CPFE has ranged from 2.1 to 8.5 years in the reported studies. The main causes of death in CPFE patients are chronic respiratory failure, pulmonary hypertension, acute exacerbation, and LC.

Patients with CPFE and LC have a poorer prognosis than those with emphysema or IPF alone. The mean overall survival of LC patients with CPFE in one study was found to be 10.8 months, which was significantly lower than the patients with emphysema (21.9 months; p=0.001).

There are currently no specific effective treatments for CPFE syndrome. Smoking cessation, which is the first treatment recommended for COPD and IPF, should also be encouraged for CPFE. Quitting smoking can stop the progression of the disease. For those with other environmental exposure to what may be harmful, it is most important to avoid such exposure. To reduce acute exacerbation and infection, prolonged oxygen therapy for the illness, and vaccination against the flu and streptococcal pneumonia are recommended.

Oxygen therapy for patients with CPFE is thought to be the most appropriate treatment for hypoxemia and pulmonary hypertension. The use of inhaled bronchodilators in patients with obstruction or mixed ventilation dysfunction is sometimes a common practice. However, it is not known whether patients with CPFE benefit from bronchodilators. The efficacy of pirfenidone and nintedanib in CPFE patients is still poorly understood. More clinical trials are needed to reach a conclusion. Lung transplantation may be the only reasonable method to improve survival in patients with advanced CPFE.

CONCLUSION

CPFE is a newly identified syndrome characterized by clinical features and radiologically characterized by upper lobe emphysema and lower lobe fibrosis. Since the disease is not well known, it cannot be diagnosed adequately. The
characteristic findings of CPFE include smoking, and it is also known that CPFE is an important risk factor for LC. Further research is needed both to clarify whether CPFE is an independent risk factor for LC and also to develop new effective therapeutic strategies.

**Informed Consent**

Written informed consent was obtained from the patient for the publication of the case report and the accompanying images.

**Peer-review**

Internally peer-reviewed.

**Authorship Contributions**


**Conflict of Interest**

None declared.

**REFERENCES**

3. Özçelik N, Özsu S. A newly-defined entity: combined pulmonary fibrosis and emphysema syndrome [Article in Turkish]. Tuberk Toraka 2015;63:48–52. [CrossRef]